Premium-Grade Research Peptides You Can Trust!!
When the peptide Semaglutide is injected, it acts as an agonist to GLP-1 receptors in the body, which helps to stimulate insulin production, reduce glucagon secretion, and delay gastric emptying. This can help to reduce blood glucose levels and further improve glycemic control.
As a result, users can experience reduced appetite which often leads to weight loss. Other known benefits are improved heart, liver, and lung function and the slowing/prevention of Alzheimer’s disease. Improved mood, better sleep quality, and reduced fatigue have also been reported.
Semaglutide should not be used as a quick fix or “miracle” weight loss regimen. However, it can be a helpful aid to establishing healthy eating habits.
Semaglutide is an effective agent for glycemic control and is especially beneficial for those with type 2 diabetes. Treatment with Semaglutide has been shown to reduce A1C levels, fasting glucose levels, and the risk of cardiovascular events in patients with type 2 diabetes (likely due to the fact that Semaglutide helps to reduce blood pressure and LDL cholesterol).
Please note that every individual needs a different dosage of Semaglutide, depending on their body’s need and size, and like all peptides, every individual’s results may vary. Semaglutide may cause mild nausea, diarrhea, constipation, and mild headaches in some cases. If any of these side effects occur, users should decrease their dosage.
Enhanced purity standards with third-party verification and GMP certification.
Recommended Dose: Inject 5 units (500mcg) daily.
Administration: Subcutaneous injection
Timing: On an empty stomach, at least 1 hour before/after eating..
Cycle: Best results occur when taken consistently for 4-12 weeks.
99% Purity tested via HPLC methods.
Store in a cool and dry place away from children.
1 vial, all supplies included
2 vials, all supplies included
Using our dosage recommendations listed above, 1 vial will provide 40 500mcg (5 unit) doses, lasting 5.71 weeks.Due to the overage of peptide solution in the vial, we provide extra syringes and wipes to ensure the entirety of the vial can be used, if desired. However, only 28 doses are needed for the 4 week protocol.
Using our dosage recommendations listed above, 3 vials will provide 120 500mcg (5 unit) doses, lasting 17.14 weeks.Due to the overage of peptide solution in the vial, we provide extra syringes and wipes to ensure the entirety of the vials can be used, if desired. However, only 84 doses are needed for the 12 week protocol.
Published in 2021 in the New England Journal of Medicine, this pivotal trial in 1,961 adults with overweight or obesity (without diabetes) showed that once-weekly subcutaneous semaglutide plus lifestyle intervention led to a mean 14.9% body weight loss at 68 weeks (vs. 2.4% with placebo), with 86% achieving ≥5% loss and superior improvements in cardiometabolic risk factors, establishing it as a game-changer for obesity management.
Read StudyPublished in 2023 in the New England Journal of Medicine, this large cardiovascular outcomes trial in 17,604 patients with preexisting CVD and overweight/obesity (without diabetes) demonstrated that semaglutide reduced major adverse cardiovascular events (CV death, nonfatal MI, or stroke) by 20% vs. placebo over ~40 months, extending CV protection beyond diabetes populations.
Read StudyPublished in 2024 in the New England Journal of Medicine, this trial in 3,533 patients with type 2 diabetes and CKD showed semaglutide reduced the risk of major kidney events (e.g., kidney failure, ≥50% eGFR decline) and CV death by 24% vs. placebo over 3.4 years, with benefits on eGFR slope and secondary CV outcomes, positioning it as a renoprotective therapy.
Read Study



Based on 0 reviews
You must be logged in to post a review.
There are no reviews yet.
Reviews